From September 14–20, 2026, the main MedTech themes were more concrete approaches to generative-AI evaluation and progress in robotic endoscopy and surgery.
Japan's PMDA released draft review considerations, while Japan also clarified continued use of a digital therapeutic under its selected medical-care framework. The following nine developments cover robotic instruments, clinical AI, hospital operations and Asahi Kasei Medical's investment.
1. PMDA Publishes Draft Review Considerations for Generative-AI Medical Devices
Published: September 18, 2026; draft dated September 14
Japan's PMDA published draft review considerations for generative-AI medical devices and opened comments through March 17, 2027. The main focus is software built around large language models (LLMs) or vision-language models (VLMs) that generates responses to natural-language or voice input.
The draft addresses hallucinations, output variability, third-party foundation models, training-data visibility, prompts and conversational context, retrieval-augmented generation, agentic autonomy and model updates. Guardrails, performance stability, human factors and post-market monitoring are also discussed.
PMDA explicitly presents this as an initial framework without prior review experience for these devices, not a finalized set of universal requirements. Developers targeting Japan will need to consider how to control the complete product, including externally supplied models and changes.
Sources
PMDA — SaMD review considerations: public consultation
PMDA — Generative-AI medical-device review considerations (Draft, PDF)
2. FDA Launches a Regulatory Reliance Portal for Medical Devices
Published: September 14, 2026
FDA CDRH launched a portal supporting the use of other authorities' regulatory assessments and information. It brings together resources on FDA pathways, public databases, inspections and post-market safety.
Foreign authorization does not automatically become U.S. authorization. The relying authority retains responsibility for its decisions. The portal is a useful reference when aligning technical documentation, clinical evidence and post-market information across jurisdictions.
Sources
FDA — CDRH Regulatory Reliance Portal for Medical Devices
FDA — CDRH New: News and Updates
3. Japan Adds a Continued-Use Pathway for Digital Therapeutic ENDEAVORRIDE
Published: September 16, 2026
Japan's Central Social Insurance Medical Council received a report that third and subsequent uses of Shionogi's ENDEAVORRIDE will fall under the selected medical-care framework from October 1, 2026. Public insurance currently covers up to two uses per patient.
ENDEAVORRIDE is a video-game-based treatment adjunct for pediatric ADHD when environmental and psychosocial interventions have not provided sufficient improvement. Government materials report improvement in inattention scores in a study of patients aged 6 to under 18.
For digital therapeutics, the funding of repeated use matters alongside authorization. This case clarifies how continued treatment beyond the insured limit will be handled in Japan.
Sources
MHLW — Central Social Insurance Medical Council, meeting 657
MHLW — Selected medical care for program medical devices (PDF)
4. Neptune Medical Announces FDA Clearance for Triton 1 Robotic Colonoscopy
Company announcement: September 16, 2026 / FDA decision: September 3, 2026
Neptune Medical announced FDA 510(k) clearance for Triton 1, listed under K260503. FDA records show a September 3 decision; September 16 is the company's announcement date.
The platform uses Dynamic Rigidization technology to improve control and stability in diagnostic and therapeutic colonoscopy, with EMR and ESD among the procedures discussed by the company. Previously reported results from the 50-patient CARE 1 study included 100% cecal intubation, a 54.2% adenoma detection rate, no adverse events and a 67% lower average operator workload by NASA-TLX compared with manual colonoscopy.
These are company-reported early single-arm results and do not establish superiority over conventional colonoscopy. Further evidence will be important in assessing the platform's ergonomic and procedural benefits.
Sources
Neptune Medical — FDA clearance announcement (Business Wire release, reproduced by BioSpace)
FDA — Triton 1 System, 510(k) K260503
Neptune Medical — 50-patient CARE 1 study (May 5, 2026)
5. FDA Clears Medtronic's LigaSure RAS Maryland for Hugo RAS
Published: September 16, 2026
Medtronic announced FDA clearance for LigaSure RAS Maryland for use with Hugo RAS. It is the company's first robotically driven LigaSure instrument and expands Hugo's U.S. instrument portfolio.
Used with Valleylab FT10, it seals and divides vessels up to 7 mm and other indicated tissue. Medtronic reports sealing in approximately two seconds. Hugo's U.S. clearance covers urologic surgery; expansion into general and gynecologic surgery remains a development plan.
Sources
Medtronic — FDA clearance for LigaSure RAS Maryland on Hugo RAS
6. Qure.ai Announces EU MDR Class IIb Certification for LLM-Based Aira
Published: September 17, 2026
Qure.ai announced Class IIb CE certification under EU MDR for Aira, its clinical decision-support system. This is based on the manufacturer's announcement and does not mean that every generative-AI function is certified without restriction.
The company has described Aira as LLM-based, combining documentation, patient-data analysis, guideline-based decision support and follow-up. Alongside PMDA's draft, the announcement highlights the need to define each product's intended use and the functions actually assessed.
Sources
Qure.ai — Aira Class IIb CE certification
Qure.ai — AIRA launch and LLM architecture (May 21, 2025)
7. GE HealthCare Introduces AI to Predict Hospital Constraints 72 Hours Ahead
Published: September 15, 2026
GE HealthCare announced CareIntellect for Operations, an AI-enabled SaaS application. It uses information on beds, staffing, patient delays and imaging to forecast capacity constraints up to 72 hours ahead.
It recommends actions around discharge, tests and transfers, with two academic medical centers expected as initial adopters. This is a hospital-operations offering, not an announcement of diagnostic-device authorization, and illustrates expansion into operational AI services.
Sources
GE HealthCare — CareIntellect for Operations (Business Wire)
8. Asahi Kasei Medical Co-Leads FIZE Series B and Expands European Distribution
Published: September 17, 2026
FIZE Medical announced the first close of a Series B round targeting $20 million, co-led by Asahi Kasei Medical and Rapha Capital Management. The first-close amount was not disclosed; the announcement does not establish that the entire $20 million has been raised.
FIZE kUO provides continuous digital urine-output monitoring and is commercially available in Japan, Europe and the U.S. Asahi Kasei Medical, its exclusive Japanese distributor, will also handle European distribution.
Proceeds will support FIZE Optima, designed to predict fluid-related risk and support treatment decisions using continuous physiological data. The partnership combines Japanese market entry, equity investment and international distribution.
Sources
FIZE Medical — Series B first close (PR Newswire)
9. Safety: FDA Updates Bravo CF Delivery-Device Recall to Class I
FDA communication update: September 15, 2026
FDA announced that the recall of certain Medtronic/Given Imaging Bravo CF esophageal pH capsule delivery devices was classified as Class I. Capsules may fail to attach to the esophagus or release correctly from the delivery device.
Reported risks include aspiration, esophageal perforation, airway obstruction, bleeding and diagnostic delays. As of August 10, 2026, 184 serious injuries and no deaths had been reported. FDA advises stopping use, quarantining and returning affected devices; the notice specifies the products and lots involved.
Sources
FDA — Bravo CF esophageal pH capsule delivery-device recall
Summary
PMDA's draft, Neptune's Triton 1 clearance announcement and Aira's EU certification show regulatory and product-development activity progressing in parallel.
ENDEAVORRIDE's continued-use pathway and FIZE's distribution partnership also underscore the importance of considering funding, commercialization, model changes and post-market management alongside authorization.